AR
TNDM icon

Advisory Research’s Tandem Diabetes Care TNDM Stock Holding History

Advisory Research’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-15,556
Closed -$917K – 341
2019
Q3 		$917K Sell
15,556
-513
-3% -$32.7K 0.04% 200
2019
Q2 		$1.04M Buy
+16,069
New +$1.04M 0.02% 250

Other funds holding TNDM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Advisory Research's TNDM Position: Q4 2019 in Review

Advisory Research sold out of Tandem Diabetes Care (TNDM) in Q4 2019, closing a stake of 15,556 shares — an estimated $917K sold.

Advisory Research first reported a position in TNDM in Q2 2019 and held it in 2 quarters. The position peaked at $1.04M in Q2 2019. 284 funds tracked by Wall St. Rank hold TNDM as of Q4 2019.

  • Advisory Research reported no remaining Tandem Diabetes Care position as of Q4 2019 after selling out during the quarter.
  • Advisory Research sold 15,556 Tandem Diabetes Care shares in Q4 2019, an estimated $917K.
  • Advisory Research first reported a position in Tandem Diabetes Care in Q2 2019 and held it in 2 quarters.
  • Advisory Research's Tandem Diabetes Care position peaked at $1.04M in Q2 2019.
  • 284 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2019.

Based on Advisory Research's 13F filing for Q4 2019, filed 11 Feb 2020.